https://www.newhavenbiz.com/edition/2020-03-01
Cybrexa CEO Per Hellsund Provides Perspective on Innovation and Leadership
Cybrexa’s CEO and Scientific Co-Founder With Personal Missions to Fight Cancer Featured in New Haven Biz
https://www.newhavenbiz.com/article/some-of-new-havens-leading-scientists-and-biotech-industry-leaders-are-on-a-personal
Live From ASCO, Cybrexa is Featured on OncologyTube-Enabling New Treatments for High Unmet Need Populations
https://www.oncologytube.com/video/strategy-of-alphalex-developement-the-agnostic-nature-of-the-platform-allows-us-to-bring-therapeutics-to-a-wider-patient-population/10006440
https://www.oncologytube.com/video/why-is-cbx-11-data-significant-our-platform-technology-is-specific-only-delivers-the-molecule-to-the-tumor-can-go-in-combo-with-high-dose-chemotherapeutic-agents/10006443
Live From ASCO, Cybrexa is Featured on OncologyTube-How Does alphalex Work?
https://www.oncologytube.com/video/what-is-alphalex-how-does-it-work-makes-use-of-acidic-tumor-environment-to-deliver-anti-cancer-agents-directly-into-the-tumor/10006441
https://www.oncologytube.com/video/how-is-alphalex-different-its-an-antigen-agnostic-tumor-targeting-technology-can-target-almost-any-solid-tumor-in-theory/10006439
Cybrexa Therapeutics in Pharma Technology Focus
Cybrexa, a spin-out company from Yale University, is developing a new class of cancer therapeutics, looking to identify combinations of chemotherapy and DNA inhibitors to increase efficacy and reduce toxicity in cancer treatment. Abi Millar spoke to the company to find out more about its approach to oncology.
Cybrexa Therapeutics in the Hartford Courant
Jan 03, 2019
Cybrexa Therapeutics, a biotechnology company in New Haven’s Science Park, hopes to start a trial in early 2020 to test its first drug, a therapy that targets the cells of solid tumors to prevent damage to healthy tissue. Cybrexa has now identified a lead candidate for the drug, CBX-11, marking a major milestone for the company, president and CEO Per Hellsund said Wednesday.
Read the full article HERE.
Cybrexa Therapeutics in BioWorld
Cybrexa Therapeutics, a New Haven, Conn.-based company developing a solid tumor-targeting technology to work with an already-approved PARP inhibitor, said it plans to submit an investigational new drug application for its lead candidate, CBX-11, by the fourth quarter of 2019. A phase I trial evaluating the drug is expected to begin in the first quarter of 2020. If preclinical findings hold, the approach could potentially enhance the therapeutic index of the PARP inhibitor, improve overall survival and limit the toxicities associated with combining PARP inhibitors and DNA-damaging chemotherapy.
Cybrexa featured in BioCentury Innovations
CYBREXA: PH-BASED TUMOR TARGETING
By Chris Lieu, Staff Writer
Cybrexa Therapeutics Inc. is developing a targeting technology that taps the pH of the tumor microenvironment to enhance the delivery specificity and decrease the toxicity of small molecule cancer therapies, starting with PARP inhibitors.
Cybrexa uses its alphalex technology to conjugate a cancer agent to a pH-sensitive peptide via an undisclosed linker. The peptide forms a transmembrane α-helix only at a low pH, which occurs in the tumor microenvironment but not normal tissues, and translocates into cells along with its cargo via a non-endocytotic route. Cytoplasmic glutathione cleaves the linker, releasing the free cancer agent inside the cancer cell.
Cybrexa has applied the alphalex technology to PARP inhibitors first because in DNA damage response (DDR)-proficient cancers, PARP inhibitors are most effective in combination with chemotherapy, but the combination leads to toxicities including myelosuppression, nephrotoxicity and hepatotoxicity, said President and CEO Per Hellsund.
View the PDF here.
Cybrexa Featured on Health Professionals Radio
Nov 23, 2018
Dr. Ranjit Bindra, Cybrexa’s chief scientific adviser, discusses Cybrexa’s technology on Health Professionals Radio: